The Universitätsklinikum Erlangen group first reported in 2021 that autologous CD19 CAR-T cell therapy induced sustained drug-free remission (≥18 months) in refractory SLE patients (14). The gene discussed is CD19; the disease is systemic lupus erythematosus.